Uncomplicating the macrovascular complications of diabetes: The 2014 edwin bierman award lecture

Diabetes

Volumn 64, Issue 8, 2015, Pages 2689-2697

  Bornfeldt, Karin E ^a,b  

^a Department of Medicine   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LIPID;

ARTERY WALL; ARTICLE; ATHEROSCLEROSIS; BONE MARROW CELL; CELL ACTIVATION; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE COURSE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROVASCULAR COMPLICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REMISSION; ANIMAL; AWARDS AND PRIZES; COMPLICATION; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; MOUSE; PATHOLOGY;

ANIMALS; AWARDS AND PRIZES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; MICE;

EID: 84962364627     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-1963     Document Type: Article

References (105)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.
2. Laing SP, Swerdlow AJ, Slater SD, et al. Mortality from heart disease in a cohort of 23, 000 patients with insulin- Treated diabetes. Diabetologia 2003;46: 760-765.
3. Orchard TJ, Costacou T, Kretowski A, Nesto RW. Type 1 diabetes and coronary artery disease. Diabetes Care 2006;29:2528-2538.
4. Taylor KS, Heneghan CJ, Farmer AJ, et al. All-cause and cardiovascular mortality in middle- Aged people with type 2 diabetes compared with people without diabetes in a large U.K. primary care database. Diabetes Care 2013;36: 2366-2371.
5. Lachin JM, Orchard TJ, Nathan DM; DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2014;37:39-43.
6. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: A scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 2014;37:2843-2863.
7. Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 2012;9:e1001321.
8. Ross R. Atherosclerosis- An inflammatory disease. N Engl J Med 1999; 340:115-126.
9. Williams KJ, Tabas I. The response- To-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995;15:551-561.
10. Tannock LR, King VL. Proteoglycan mediated lipoprotein retention: A mechanism of diabetic atherosclerosis. Rev Endocr Metab Disord 2008;9:289-300.
11. Strandness DE Jr, Priest RE, Gibbons GE. Combined clinical and pathologic study of diabetic and nondiabetic peripheral arterial disease. Diabetes 1964;13: 366-372.
12. Virmani R, Burke AP, Kolodgie F. Morphological characteristics of coronary atherosclerosis in diabetes mellitus. Can J Cardiol 2006;22(Suppl. B):81B-84B.
13. Willecke F, Scerbo D, Nagareddy P, et al. Lipolysis, and not hepatic lipogenesis, is the primary modulator of triglyceride levels in streptozotocininduced diabetic mice. Arterioscler Thromb Vasc Biol 2015;35:102-110.
14. Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest 1996;97:1767-1773.
15. Renard CB, Kramer F, Johansson F, et al. Diabetes and diabetesassociated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J Clin Invest 2004;114:659-668.
16. Van Belle TL, Taylor P, von Herrath MG. Mouse models for type 1 diabetes. Drug Discov Today Dis Models 2009;6:41-45.
17. Holz A, Dyrberg T, Hagopian W, Homann D, von Herrath M, Oldstone MB. Neither B lymphocytes nor antibodies directed against self antigens of the islets of Langerhans are required for development of virus-induced autoimmune diabetes. J Immunol 2000;165:5945-5953.
18. Lamharzi N, Renard CB, Kramer F, et al. Hyperlipidemia in concert with hyperglycemia stimulates the proliferation of macrophages in atherosclerotic lesions: potential role of glucose-oxidized LDL. Diabetes 2004;53:3217-3225.
19. Johansson F, Kramer F, Barnhart S, et al. Type 1 diabetes promotes disruption of advanced atherosclerotic lesions in LDL receptor-deficient mice. Proc Natl Acad Sci U S A 2008;105:2082-2087.
20. Bornfeldt KE. 2013 Russell Ross Memorial Lecture in vascular biology: cellular and molecular mechanisms of diabetes mellitus- Accelerated atherosclerosis. Arterioscler Thromb Vasc Biol 2014;34:705-714.
21. Taborsky GJ Jr, Mei Q, Bornfeldt KE, Hackney DJ, Mundinger TO. The p75 neurotrophin receptor is required for the major loss of sympathetic nerves from islets under autoimmune attack. Diabetes 2014;63:2369-2379.
22. Parathath S, Grauer L, Huang LS, et al. Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes 2011;60: 1759-1769.
23. Nagareddy PR, Murphy AJ, Stirzaker RA, et al. Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 2013;17: 695-708.
24. Elias D, Prigozin H, Polak N, Rapoport M, Lohse AW, Cohen IR. Autoimmune diabetes induced by the beta-cell toxin STZ. Immunity to the 60-kDa heat shock protein and to insulin. Diabetes 1994;43:992-998.
25. Lowe G, Woodward M, Hillis G, et al. Circulating inflammatory markers and the risk of vascular complications and mortality in people with type 2 diabetes and cardiovascular disease or risk factors: The ADVANCE study. Diabetes 2014;63:1115-1123.
26. Sajadi SM, Khoramdelazad H, Hassanshahi G, et al. Plasma levels of CXCL1 (GRO- Alpha) and CXCL10 (IP-10) are elevated in type 2 diabetic patients: Evidence for the involvement of inflammation and angiogenesis/angiostasis in this disease state. Clin Lab 2013;59:133-137.
27. Basu S, Larsson A, Vessby J, Vessby B, Berne C. Type 1 diabetes is associated with increased cyclooxygenase- And cytokine-mediated inflammation. Diabetes Care 2005;28:1371-1375.
28. Piemonti L, Calori G, Lattuada G, et al. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle- Aged diabetic and nondiabetic individuals. Diabetes Care 2009;32:2105-2110.
29. Shah R, Hinkle CC, Ferguson JF, et al. Fractalkine is a novel human adipochemokine associated with type 2 diabetes. Diabetes 2011;60:1512-1518.
30. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006;55:774-779.
31. Levy H, Wang X, Kaldunski M, et al. Transcriptional signatures as a diseasespecific and predictive inflammatory biomarker for type 1 diabetes. Genes Immun 2012;13:593-604.
32. Bradshaw EM, Raddassi K, Elyaman W, et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. J Immunol 2009;183:4432-4439.
33. Kanter JE, Bornfeldt KE. Inflammation and diabetes- Accelerated atherosclerosis: myeloid cell mediators. Trends Endocrinol Metab 2013;24:137-144.
34. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity 2014;41:36-48.
35. Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis. Am Heart J 2013;166:199-207, e15.
36. Ridker PM. Closing the loop on inflammation and atherothrombosis: Why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc 2013;124: 174-190.
37. Chan ES, Cronstein BN. Methotrexate-how does it really work? Nat Rev Rheumatol 2010;6:175-178.
38. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1b inhibition and the prevention of recurrent cardiovascular events: Rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605.
39. Hensen J, Howard CP, Walter V, Thuren T. Impact of interleukin-1b antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial. Diabetes Metab 2013;39:524-531.
40. Nicholls SJ, Kastelein JJ, Schwartz GG, et al.; VISTA-16 Investigators. Varespladib and cardiovascular events in patients with an acute coronary syndrome: The VISTA-16 randomized clinical trial. JAMA 2014;311:252-262.
41. Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: A population-based cohort study. Circulation 2014;130:837-844.
42. Bouma G, Lam-Tse WK, Wierenga-Wolf AF, Drexhage HA, Versnel MA. Increased serum levels of MRP-8/14 in type 1 diabetes induce an increased expression of CD11b and an enhanced adhesion of circulating monocytes to fibronectin. Diabetes 2004;53:1979-1986.
43. Jin Y, Sharma A, Carey C, et al. The expression of inflammatory genes is upregulated in peripheral blood of patients with type 1 diabetes. Diabetes Care 2013;36:2794-2802.
44. Ortega FJ, Sabater M, Moreno-Navarrete JM, et al. Serum and urinary concentrations of calprotectin as markers of insulin resistance and type 2 diabetes. Eur J Endocrinol 2012;167:569-578.
45. Healy AM, Pickard MD, Pradhan AD, et al. Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 2006;113:2278-2284.
46. Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol 2012;32:223-229.
47. Kanter JE, Kramer F, Barnhart S, et al. Diabetes promotes an inflammatory macrophage phenotype and atherosclerosis through acyl-CoA synthetase 1. Proc Natl Acad Sci U S A 2012;109:E715-E724.
48. Rubinow KB, Wall VZ, Nelson J, et al. Acyl-CoA synthetase 1 is induced by Gram-negative bacteria and lipopolysaccharide and is required for phospholipid turnover in stimulated macrophages. J Biol Chem 2013;288:9957-9970.
49. Huang YL, Morales-Rosado J, Ray J, et al. Toll-like receptor agonists promote prolonged triglyceride storage in macrophages. J Biol Chem 2014;289:3001-3012.
50. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997; 272:28210-28217.
51. Durgan DJ, Smith JK, Hotze MA, et al. Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin. Am J Physiol Heart Circ Physiol 2006;290: H2480-H2497.
52. Rakhshandehroo M, Hooiveld G, Müller M, Kersten S. Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human. PLoS One 2009;4:e6796.
53. Li LO, Ellis JM, Paich HA, et al. Liver-specific loss of long chain acyl-CoA synthetase-1 decreases triacylglycerol synthesis and beta-oxidation and alters phospholipid fatty acid composition. J Biol Chem 2009;284:27816-27826.
54. Ellis JM, Li LO, Wu PC, et al. Adipose acyl-CoA synthetase-1 directs fatty acids toward beta-oxidation and is required for cold thermogenesis. Cell Metab 2010;12:53-64.
55. Ellis JM, Mentock SM, Depetrillo MA, et al. Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs fatty acid oxidation and induces cardiac hypertrophy. Mol Cell Biol 2011;31:1252-1262.
56. Kratz M, Coats BR, Hisert KB, et al. Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages. Cell Metab 2014;20:614-625.
57. Spann NJ, Garmire LX, McDonald JG, et al. Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell 2012;151:138-152.
58. Mathis D, Shoelson SE. Immunometabolism: An emerging frontier. Nat Rev Immunol 2011;11:81.
59. Recio C, Oguiza A, Lazaro I, Mallavia B, Egido J, Gomez-Guerrero C. Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice. Arterioscler Thromb Vasc Biol 2014;34: 1953-1960.
60. Nathan DM, Cleary PA, Backlund JY, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653.
61. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucoselowering drugs or strategies in type 2 diabetes. Lancet 2014;383:2008-2017.
62. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
63. Vasamsetti SB, Karnewar S, Kanugula AK, Thatipalli AR, Kumar JM, Kotamraju S. Metformin inhibits monocyte- To-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis. Diabetes 2015;64:2028-2041.
64. Forouzandeh F, Salazar G, Patrushev N, et al. Metformin beyond diabetes: pleiotropic benefits of metformin in attenuation of atherosclerosis. J Am Heart Assoc 2014;3:e001202.
65. Riksen NP, Tack CJ. The cardiovascular effects of metformin: lost in translation? Curr Opin Lipidol 2014;25:446-451.
66. Sofer E, Boaz M, Matas Z, Mashavi M, Shargorodsky M. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: A randomized, placebo-controlled trial. Metabolism 2011;60:1278-1284.
67. Abbasi F, Chu JW, McLaughlin T, Lamendola C, Leary ET, Reaven GM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004;53:159-164.
68. Reaven P, Merat S, Casanada F, Sutphin M, Palinski W. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptordeficient mice. Arterioscler Thromb Vasc Biol 1997;17:2250-2256.
69. Tahara A, Kurosaki E, Yokono M, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol 2013;715: 246-255.
70. Adiels M, Borén J, Caslake MJ, et al. Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2005;25:1697-1703.
71. Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 2011;31:513-519.
72. Crosby J, Peloso GM, Auer PL, et al.; TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-offunction mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 2014;371:22-31.
73. Jørgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 2014;371:32-41.
74. Distel E, Barrett TJ, Chung K, et al. miR33 inhibition overcomes deleterious effects of diabetes mellitus on atherosclerosis plaque regression in mice. Circ Res 2014;115:759-769.
75. Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121:2921-2931.
76. De Nardo D, Labzin LI, Kono H, et al. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 2014;15:152-160.
77. Suzuki M, Pritchard DK, Becker L, et al. High-density lipoprotein suppresses the type I interferon response, a family of potent antiviral immunoregulators, in macrophages challenged with lipopolysaccharide. Circulation 2010; 122:1919-1927.
78. Nagareddy PR, Kraakman M, Masters SL, et al. Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity. Cell Metab 2014;19: 821-835.
79. Nishizawa T, Kanter JE, Kramer F, et al. Testing the role of myeloid cell glucose flux in inflammation and atherosclerosis. Cell Reports 2014;7:356-365.
80. Krawczyk CM, Holowka T, Sun J, et al. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 2010;115:4742- 4749.
81. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013;493:346-355.
82. Tan Z, Xie N, Banerjee S, et al. The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages. J Biol Chem 2015;290:46-55.
83. Ruiz-García A, Monsalve E, Novellasdemunt L, et al. Cooperation of adenosine with macrophage Toll-4 receptor agonists leads to increased glycolytic flux through the enhanced expression of PFKFB3 gene. J Biol Chem 2011;286: 19247-19258.
84. Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1b through HIF-1a. Nature 2013;496:238-242.
85. Gautier EL, Westerterp M, Bhagwat N, et al. HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 2013;210:339-353.
86. Freemerman AJ, Johnson AR, Sacks GN, et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem 2014;289:7884-7896.
87. Bornfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011;14:575-585.
88. Lewis P, Stefanovic N, Pete J, et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein Edeficient mice. Circulation 2007;115:2178-2187.
89. Gray SP, Di Marco E, Okabe J, et al. NADPH oxidase 1 plays a key role in diabetes mellitus- Accelerated atherosclerosis. Circulation 2013;127:1888-1902.
90. Geoffrion M, Du X, Irshad Z, et al. Differential effects of glyoxalase 1 overexpression on diabetic atherosclerosis and renal dysfunction in streptozotocintreated, apolipoprotein E-deficient mice. Physiol Rep 2014;2:e12043.
91. Hanssen NM, Brouwers O, Gijbels MJ, et al. Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes. Cardiovasc Res 2014;104:160-170.
92. Yan SF, Ramasamy R, Schmidt AM. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev Mol Med 2009;11:e9.
93. Koulis C, Kanellakis P, Pickering RJ, et al. Role of bone-marrow- And nonbone- marrow-derived receptor for advanced glycation end-products (RAGE) in a mouse model of diabetes- Associated atherosclerosis. Clin Sci (Lond) 2014;127: 485-497.
94. Soro-Paavonen A, Watson AM, Li J, et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461-2469.
95. Kong L, Shen X, Lin L, et al. PKCb promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice. Arterioscler Thromb Vasc Biol 2013;33:1779-1787.
96. DCCT/EDIC Research Group. Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long- Term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol 2014;2:793-800.
97. van der Velde M, Matsushita K, Coresh J, et al.; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta- Analysis of high-risk population cohorts. Kidney Int 2011;79: 1341-1352.
98. Schwartz MW, Seeley RJ, Tschöp MH, et al. Cooperation between brain and islet in glucose homeostasis and diabetes. Nature 2013;503:59-66.
99. Rask-Madsen C, Li Q, Freund B, et al. Loss of insulin signaling in vascular endothelial cells accelerates atherosclerosis in apolipoprotein E null mice. Cell Metab 2010;11:379-389.
100. Baumgartl J, Baudler S, Scherner M, et al. Myeloid lineage cell-restricted insulin resistance protects apolipoprotein E-deficient mice against atherosclerosis [published correction appears in Cell Metab 2006;3:469]. Cell Metab 2006;3: 247-256.
101. Han S, Liang CP, DeVries-Seimon T, et al. Macrophage insulin receptor deficiency increases ER stress-induced apoptosis and necrotic core formation in advanced atherosclerotic lesions. Cell Metab 2006;3:257-266.
102. Liang CP, Han S, Senokuchi T, Tall AR. The macrophage at the crossroads of insulin resistance and atherosclerosis. Circ Res 2007;100:1546-1555.
103. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 2011;31:1716-1725.
104. Miller M, Stone NJ, Ballantyne C, et al.; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. Circulation 2011; 123:2292-2333.
105. Ståhlman M, Fagerberg B, Adiels M, et al. Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles. Biochim Biophys Acta 2013;1831:1609-1617.